Search Press releases Keywords From To 9 Nov 2005 UCB Receives FDA Orphan Drug Designation for Brivaracetam for the Treatment of Symptomatic Myoclonus Read More 27 Oct 2005 UCB Reports Positive Clinical Trial Results for Keppra® as Adjunctive Therapy in the Treatment of Primary Generalised Tonic-Clonic Seizures Read More 20 Oct 2005 UCB confirms good performance of Zyrtec in US and Xyzal Read More 18 Oct 2005 UCB: Phase III study shows CIMZIA(TM) is an effective and well-tolerated treatment for Crohn's disease Read More 22 Sep 2005 European Commission Approves Use of UCB's Anti-Epileptic Keppra® as Adjunctive Therapy in Children Four Years of Age and Older with Partial-Onset Seizures Read More 15 Sep 2005 UCB'S ANTI-EPILECTIC KEPPRA® MEETS PRIMARY END-POINT IN MONOTHERAPY TRIAL Read More Pagination First page Previous page Previous … Page 185 Page 186 Page 187 Page 188 Current page 189 Page 190 Page 191 Page 192 Page 193 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe